Vasoactive intestinal peptide receptors 1 (VPAC1) and 2 (VPAC2) have been identified in humans. Cell lines expressing only VPAC1 (HT-29) or VPAC2 (Molt-4b) were identified using real-time reverse transcriptase polymerase chain reaction. Vasoactive intestinal peptide (VIP) and related peptides, VIP Ϫ6 -28 , VIP , previously isolated from cultures of human leukocytes, were evaluated for their ability to bind to VPAC1 and VPAC2 and to increase the levels of cAMP in HT-29 and Molt-4b cells. VIP bound to membranes of HT-29 colon carcinoma cells and Molt-4b lymphoblasts with high affinity (K D ϭ 1.6 Ϯ 0.2 and 1.7 Ϯ 0.9 nM, respectively). VIP 4 -28 also demonstrated high-affinity binding (K D ϭ 1.7 Ϯ 0.2 and 1.7 Ϯ 0.7 nM in HT-29 and Molt-4b, respectively). VIP and VIP 4 -28 are potent VPAC1 agonists, inducing maximal 200-and 400-fold increases in cAMP, respectively. VIP demonstrated weak VPAC2 agonist activity, inducing a maximal 14-fold increase in cAMP. VIP 4 -28 had no VPAC2 agonist activity but demonstrated potent VPAC2 antagonist activity. VIP 4 -28 inhibited VPAC2-mediated increases in cAMP in Molt-4b cells up to 95%, but had no antagonistic effect on VPAC1. Lymphoblasts did not hydrolyze VIP 4 -28 to a form with VPAC1 antagonist activity. VIP 4 -28 thus is a lymphocyte-generated VIP fragment with potent agonist activity for VPAC1 and potent antagonist activity for VPAC2.
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Several neuroendocrine peptides, originally thought to be synthesized exclusively in nerve cells and to interact only with those tissues innervated by peptidergic neurons have been demonstrated to modulate the synthesis of cytokines and growth factors. Neutrophils, eosinophils, and basophils have been shown to synthesize peptides, including somatostatin and VIP (Goetzl et al., 1985; Goetzl et al., 1988; O'Dorisio et al., 1980) , whereas monocytes and lymphocytes express high-affinity receptors for these and other peptides (Danek et al., 1983; Ottaway et al., 1983; Scicchitano et al., 1987; Sreedharan et al., 1989) . The structure and processing of prepro-VIP seems to differ in leukocytes compared with nerve cells; leukocytes produce and secrete both truncated and N-terminally extended peptides such as VIP 10 -28 and VIP Ϫ6 -28 (Hayakawa et al., 1984; Goetzl et al., 1988) . Several VIP fragments, of which VIP 4 -28 is the most prominent, are generated from VIP by protease activity at the surface of lymphocytes (Goetzl et al., 1988) . These peptides may be released into tissue fluids at nanomolar concentrations and therefore potentially exert significant immunoregulatory and other physiological effects. This study was designed to compare VPAC1 and VPAC2 recognition of VIP and several VIP variant peptides (Goetzl et al., 1988) . Human cell lines that express only a single VIP receptor were identified by real-time RT-PCR; the relative affinities of these peptides for the two VIP receptors, VPAC1 in HT-29 colonic epithelial cells and VPAC2 in lymphoblastoid cells, were determined by competitive binding. Further experiments then examined the ability of VIP and VIP-related peptides to activate the cAMP signal transduction pathway in each cell line alone or in the presence of VIP.
Materials and Methods
Cell Culture. Molt-4b lymphoblasts (American Type Culture Collection, Manassas, VA) were grown in suspension cultures in 75-cm 2 flasks (Corning, Palo Alto, CA) in culture media consisting of RPMI 1640 medium with 15% heat-inactivated fetal bovine serum supplemented to final concentrations of 4 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. HT-29 colon carcinoma cells (American Type Culture Collection) were cultured as monolayers in 75-cm 2 flasks (Corning) in culture medium consisting of RPMI 1640 medium with 10% heat inactivated fetal bovine serum supplemented as described above. All media components were from Invitrogen (Carlsbad, CA). Cells were incubated at 37°in 5% CO 2 and grown to Ͼ90% confluence for membrane harvest or for signal transduction studies. Before use, cells were washed twice with Seligman's balanced salt solution (Invitrogen). Cell number was evaluated by means of a Coulter counter. Cell viability was determined by trypan blue exclusion.
Real-Time RT-PCR. Real-Time RT-PCR was performed using the 5Ј-3Ј nuclease activity of Taq polymerase to allow direct detection of the product by the release of a fluorescent reporter dye from a specific fluorescent-labeled probe during the PCR reaction. The probe consists of an oligonucleotide with a 5Ј-reporter dye (6-carboxyfluorescein) or VIC dye and 3Ј-quencher dye 6-carboxytetramethylrhodamine (TAMRA) (Applied Biosystems, Foster City, CA). Specific primers were designed for real-time RT-PCR of VPAC1, 5Ј-ACA AGG CAG CGA GTT TGG AT-3Ј and 5Ј-GTG CAG TGG AGC TTC CTG AAC-3Ј; VPAC2, 5Ј-CGT GAA CAG CAT TCA CCC AGA AT-3 and 5Ј-CGT GAC GGT CTC TCC CAC AT-3Ј; and rRNA, 5ЈCG-GCTACCACATCCAAGGAA-3Ј and 5Ј-GCTGGAATTACCGCGGCT-3Ј. The probes for VPAC1, CCACCCTTCTGGTCGCCACAGCTAT-TAMRA and VPAC2, AACACAAAGCCTGCAGTGGCGTCTG-TAMRA were labeled with 6-carboxyfluorescein. The rRNA probe TGCTGGCACCAGACTTGCCCTC-TAMRA was labeled with VIC, which has a different spectrum than the reporter dye of the VPAC1 and VPAC2 probes. The rRNA was used to ensure quality of RNA preparation, to account for efficiency of the reverse transcription, and to control for any loading variation of the initial cDNA amount. One standard curve for the target gene (VPAC1 or VPAC2), and one standard curve for the rRNA gene were generated for quantification. The rRNA standard curve was generated with known (picogram) amounts of a cloned rRNA gene (Lara-Marquez et al., 2001) to determine the relative expression of rRNA in each sample. Serial dilutions of linearized plasmids containing the human VPAC1 or VPAC2 gene were used to construct a standard curve of copy number versus threshold cycle (C T ). The actual number of copies of each target gene is thus extrapolated from each standard curve. VPAC1 and VPAC2 are measured as copy number and rRNA as picograms. The copy numbers are normalized against 100 pg of rRNA. The results are expressed as copy number per 100 pg of rRNA using the following formula: copy number/100 pg of rRNA ϭ copy number of VPAC1 or VPAC2 ϫ 100/pg of rRNA of each individual sample.
Reactions were performed in a MicroAmp Optical 96-well reaction plate (Applied Biosystems) using 2.5 l of cDNA clone or unknown samples, 12.5 l of 2ϫ Master Mix [8% glycerol, 1ϫ TaqMan buffer A, 200 M dATP, 200 M dCTP, 200 M dCTP, 200 M dGTP, 400 M dUTP, 0.05 U/l AmpErase uracil N-glycosylase, 5 mM MgCl 2 , and 0.01 U/l Gold amplitaq DNA polymerase (Applied Biosystems)], forward/reverse primer (900 nM) and labeled probe for the target gene (200 nM) (VPAC1 or VPAC2), and forward/reverse primer (50 nM) and labeled probe (50 nM) for the housekeeper gene (rRNA). The final volume of the PCR reaction was brought up to 25 l. Samples of the plasmid clone only have the target gene set of primers and probe. Amplification conditions are 2 min at 50°C (to activate Amperase to prevent PCR carryover) 10 min at 95°C (to activate Gold amplitaq) for the first cycle, followed by 40 cycles with a denaturing step of 15 s at 95°C and an anneal/extension step of 1 min at 60°C. All reactions were performed in the 7700 Sequence Detector thermocycler linked to a Macintosh computer using the sequence detector software to run the PCR reaction.
Enriched Plasma Membrane Preparations. Membranes were prepared as we have described previously (O'Dorisio et al., 1988) . Cells were suspended in buffer A (20 mM HEPES, 2 mM MgCl 2 , 5 mM EDTA, 1 mM 2-mercaptoethanol, 150 mM NaCl 2 , and 50 g/ml phenylmethylsulfonyl flouride, pH 7.4) at a concentration of 5 ϫ 10 6 cells/ml buffer. Cells were subjected to ultrasonic disruption by Polytron (Brinkmann Instruments, Westbury, NY) for 30 s followed by centrifugation at 750g for 5 min. The pellet was resuspended in one-half the original volume of buffer A and disrupted by Polytron for an additional 30 s. After a second 750g spin, the two supernatant fractions were combined and centrifuged for 20 min at 48,000g. The resulting particulate fraction was washed in the original volume of buffer A and centrifuged 48,000g for 20 min. The particulate membrane fraction was resuspended in buffer A and stored at Ϫ80°until use.
Membrane Binding. Binding studies were performed as we have described previously (O'Dorisio et al., 1988) . Competition experiments for estimation of receptor number (B max ) and affinity (K D ) were performed using 100 g of membrane protein in buffer A containing 50 pM 125 I-VIP (35,000 -50,000 cpm) and increasing concentrations of unlabeled VIP or homologous peptide in a total volume of 0.5 ml.
125 I-VIP (specific activity 2200 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, MA), and synthetic VIP was purchased from Bachem (Torrance, CA). Reactions were started by the addition of membrane and the binding reaction continued under steady-state conditions for 30 min at 17°C in a shaking controlled temperature water bath. The reaction was stopped by filtering triplicate 0.15-ml aliquots of binding mixture over GF/C filters (Whatman, Maidstone, UK) presoaked in 0.3% polyethylenimine followed by triplicate washes of buffer A containing 0.2% bovine serum albumin. Radioactivity bound to filters was quantified in a Beckman Gamma 5500. Triplicates of both total and nonspecific binding were performed for every experiment. Specific binding was calculated as the difference between the means of determinations of total binding and binding in the presence of 1 M unlabeled VIP. For both cell lines, specific binding was linear over the range of 25 to 350 g of protein, total binding constituted 60 to 80% of added 125 I-VIP, and specific binding was Ͼ75% of total binding. Analysis of the data were performed using the LIGAND program (McPherson, 1985) .
Quantification of Intracellular Cyclic Nucleotides. HT-29 monolayers in 24-well plates or Molt-4b cells in suspension cultures were gently washed three times with Seligman's balanced salt solution. Triplicate wells or tubes of cells were incubated with a final volume of 1.0 ml of RPMI 1640 medium at 37°C for 5 min in the absence or presence of peptide, forskolin, or prostaglandin E 2 . Experimental drugs were dissolved in media without additives. Reactions were terminated by the addition of one-third volume of 30% trichloroacetic acid (TCA). Plates were scraped immediately; cells were transferred to high-speed centrifuge tubes. Cell suspensions were subjected to ultrasonic disruption and centrifuged at 10,000g for 10 min at 4°C. TCA was removed from supernatants by ether extraction; cyclic AMP was succinylated and quantified by radioimmunoassay as described previously by our laboratory (Chen et al., 1993) .
Concentration Dependence of Antagonism by VIP 4 -28 . cAMP dose-response curves for VIP were generated in Molt-4b cells in the presence of various concentrations of VIP 4 -28 (0, 0.1 nM, 10 nM, and 1 M), which were added simultaneously. The data were then compiled using GraphPad software (GraphPad Software, Inc., San Diego, CA) for analysis of dose-response curves in the presence of antagonists, a nonlinear analysis based on Schild plot technique. Simultaneous addition of the two peptides may not provide sufficient time for maximum binding of VIP 4 -28 (Sjoberg et al., 1987) .
Peptide Synthesis. All peptides were synthesized by automated solid phase techniques in a three-vessel model 430A system (Applied Biosystems) as described previously (Goetzl et al., 1988) . After cleavage from the resin with hydrofluoric acid, the peptides were purified by high-performance liquid chromatography (HPLC) on a 2 ϫ 25 cm octadecylsilane column in a model 1406 A system using a solvent program of 30 min of 0.1% trifluoracetic acid in water at 8 ml/min and then a 90-min gradient of 65% acetonitrile/35% 0.1% trifluoracetic acid. Identity of each peptide (Fig. 1) was evaluated by complete amino acid sequence with gas-phase Edman method in a model 470A system equipped with on line narrow bore HPLC analysis (Beckman jpet.aspetjournals.org model 120A) and automated data integration (model 900A) for quantification of parathyroid hormone amino acids. All experiments using VIP 4 -28 were also performed with peptide purchased from Bachem.
Results

VPAC1 Expression on HT-29
Colon Carcinoma Cells and VPAC2 Expression on Molt-4b Lymphoblasts. RNA was harvested from two human cell lines, HT-29 colon carcinoma and Molt-4b lymphoblastic cells, and analyzed by real-time RT-PCR. As shown in Fig. 2 , HT-29 cells express VPAC1 (4157 Ϯ 1126 copies/100 pg of rRNA, mean Ϯ S.E., n ϭ 6), but had no detectable VPAC2 mRNA (p Ͻ 0.0001). In contrast, Molt-4b cells express VPAC2 mRNA (6099 Ϯ 1440 copies/100 pg of rRNA, mean Ϯ S.E.), but nondetectable levels of VPAC1 (p Ͻ 0.0001). Fewer than 50 copies/100 pg of rRNA is considered nondetectable in the real-time PCR conditions used in this protocol. For illustration purposes in Fig.  2 and for statistical analysis, 10 copies/100 pg of rRNA has been arbitrarily designated when copy number is below the limits of detection.
High-Affinity Binding of VIP and VIP 4 -28 to VPAC1 and VPAC2. Competitive binding studies were performed on plasma membranes harvested from the HT-29 colonic epithelial cell line. VIP 4 -28 was equally as effective as VIP as a competitive inhibitor of 125 I-VIP binding (Fig. 3A) . These experiments revealed apparent identity in the affinity of receptors recognized by VIP and VIP 4 -28 with K D ϭ 1.6 and 1.7 nM, respectively (Table 1) . Using the conversion factor of 1 g of membrane protein/2.3 Ϯ 0.4 ϫ 10 6 HT-29 cells, the B max of 0.7 nM extrapolates to 85,000 VPAC1 receptors/cell.
Molt-4b lymphoblasts exhibit a single class of high affinity VIP binding sites with a K D ϭ 1.7 nM for both VIP and and VIP 4 -28 (Fig. 3B) . Analysis of the number of binding sites for each peptide using the LIGAND program revealed apparent identity between VIP and VIP 4 -28 (B max ϭ 0.7 Ϯ 0.1 and 0.8 Ϯ 0.6 nM, respectively), suggesting that the two peptides bind to the same receptor (Table 1) . Using this method of membrane preparation, 1 g of membrane protein corresponds to 9.5 Ϯ 2.9 ϫ 10 6 Molt-4b cells. The B max of 0.7 nM represents an estimated 20,000 high-affinity VPAC2 binding sites per cell, in good agreement with our previous estimate of 15,000 sites/cell (Beed et al., 1983) .
Binding of VIP ؊6 -28 and VIP 10 -28 to VPAC1 and VPAC2. The peptides VIP Ϫ6 -28 and VIP 10 -28 , were less effective inhibitors of 125 I-VIP binding in both cell lines (Fig. 3,  A Table 2) . The basal cAMP level is higher in the Molt-4b lymphoblastic cell line than in HT-29 colonic cells. However, prostaglandin E 2 induces 16-to 22-fold increases in cAMP in both cell lines and forskolin induces a 150-fold increase in cAMP in both cell lines. In contrast, VIP is a much more effective agonist in HT-29 cells than in Molt-4b cells, raising cAMP levels in HT-29 cells 225-fold over basal in 5 min compared with a 14-fold increase in Molt-4b cells. VIP 4 -28 induces Ͼ400-fold increase in cAMP levels in HT-29 cells, but has no agonist activity in Molt-4b lymphoblasts. VIP -6 -28 has agonist activity similar to VIP in both cell types, whereas VIP 10 -28 has no agonist activity in either HT-29 colonic cells or in Molt-4b lymphoblasts.
VIP 4 -28 Is VPAC1 Agonist and VPAC2 Antagonist. Dose-response curves for VIP-mediated cAMP generation in Molt-4b lymphoblasts are shown in Fig. 6 . The maximum accumulation of cAMP via VPAC2 is observed at 10 nM VIP. This effect is inhibited 95% by 1 M VIP 4 -28 (p Ͻ 0.01). Similarly, VIP 4 -28 inhibits the effects of 0.1 M VIP by 89% (p Ͻ 0.01), but does not significantly inhibit the effect of 1 M VIP (p Ͼ 0.1). The right shift of the VIP dose-response curve in the presence of 1 M VIP 4 -28 , and the fact that VIP 4 -28 does not effectively antagonize the action of an equimolar concentration of VIP, support the hypothesis that these two peptides compete for the same high-affinity receptor in Molt-4b lymphoblasts.
VIP 4 -28 Antagonism of VPAC2 Is Dose-Dependent. Dose-response curves for VIP interaction with VPAC2 were generated in Molt-4b cells in the presence of various concentrations of VIP 4 -28. Figure 7 demonstrates VIP dose-response curves in the presence of 0.1 nM, 10 nM, and 1 M VIP 4 -28 . Although VIP was able to induce full agonist activation of VPAC2 in the presence of the putative antagonist VIP 4 -28 , the slope of the resulting Schild plot is 0.59 Ϯ 0.34. 10 -28 Competitive binding experiments were performed as described under Materials and Methods. Results are mean Ϯ S.D. of four experiments, one of which is represented in Fig. 1 Addition of protease inhibitors did not enhance the ability of VIP 4 -28 to induce cAMP generation in Molt-4b lymphoblasts (Table 3) . To further test whether Molt-4b lymphocytes hydrolyze VIP 4 -28 to a peptide fragment with antagonist activity in both HT-29 and Molt-4b cells, VIP 4 -28 was added to Molt-4b lymphoblast cultures at a concentration of 1 M. After 5 min, the medium (containing VIP 4 -28 and any hydrolyzed peptides) was incubated with HT-29 cells. As can be seen in Table 4 , VIP 4 -28 had no agonist activity in Molt-4b lymphoblasts, but when transferred to colonic cells, this 
Discussion
Endogenous antagonists have now been identified for several receptors, including hepatocyte growth factor (Chan et al., 1991) and the immunoglobulin receptor (Torigoe et al., 1998) . These antagonists are pseudoreceptors or truncated receptors. Analogs of a ligand can also function as antagonists; ␤-blockers that antagonize action of endogenous ␤-adrenergic receptor ligands are among the most well known antagonists in this category (Strader et al., 1989) . Endogenous peptides are physiological antagonists of the IL-1 and IL-7 receptors (Carter et al., 1990; Granowitz et al., 1991) .
Several VIP analogs have been designed as VIP receptor antagonists. These peptide ligands include VIP 10 -28 (Turner et al., 1986) eck et al., 1985) , and neurotensin 6 -11 -VIP 7-28 (Gozes et al., 1996) . Although VIP demonstrates high-affinity binding with affinity constants in the subnanomolar range, the abovenamed antagonists all have dissociation constants in the micromolar range. We demonstrate that VIP 4 -28 has affinity equal to VIP, has potent agonist activity at VPAC1, and has potent antagonist activity at VPAC2. The first three amino acids in VIP (H, S, and D), seem to be important for stimulation of adenylate cyclase via VPAC2 as suggested by the ability of both VIP and VIP -6 -28 , but not VIP 4 -28 or VIP 10 -28 to induce cAMP accumulation in Molt-4b cells. This is consistent with the early observations of Mutt (1982) that aspartic acid in position 3 at the N-terminal end of VIP and secretin is important in cAMP generation. VIP 4 -28 thus is unique in several respects: 1) it is an endogenous peptide generated by lymphocyte proteolysis of VIP; 2) it binds with high affinity to both VPAC1 and VPAC2; and 3) it has VPAC1 agonist activity and VPAC2 antagonist activity. These observations all suggest a role for VIP 4 -28 in vivo.
Previous studies have established the presence of highaffinity VIP receptors on human intestinal epithelial cells where VIP mediates water and electrolyte secretion as well as on human T and B lymphocytes (Danek et al., 1983; . In the immune system, VIP seems to modulate lymphocyte trafficking, T cell proliferation, and B cell synthesis of IgA (Lara-Marquez et al., 2001 ). The present studies used two human cell lines as in vitro models of intestinal epithelial cells and immune cells. The Molt-4b cell line is derived from human leukemia cells. HT-29 is a colonic epithelial cell line established from a human colon carcinoma. Previous studies from our laboratory have demonstrated that VIP interacts with high-affinity receptors to stimulate adenylate cyclase, activate protein kinase A, and induce phosphorylation of an identical 38-kDa protein in both cell lines . The results presented here suggest that functional differences exist between the VPAC1 receptor expressed on HT-29 cells and the VPAC2 receptor expressed on Molt-4b lymphoblasts. Although the lymphoblastic and colonic cell receptors seem to bind VIP with equal affinity and with similar numbers of receptors per milligram of membrane protein, the HT-29 receptor complex seems to transduce a signal from VIP and VIP 4 -28 to adenylate cyclase more efficiently.
Although the number of receptors per milligram of membrane protein is quite similar in HT-29 cells and Molt-4b lymphoblasts, the number of VIP receptors per cell is 4-fold greater in HT-29 cells; this may account partially for the higher stimulation index for VIP in HT-29 cells. However, the finding that VIP 4 -28 stimulates cAMP generation in HT-29 cells and inhibits VIP-mediated cAMP accumulation in Molt-4b lymphoblasts demonstrates that VPAC1 and VPAC2 are functionally quite different receptors.
The ␣ and ␤ subtypes of adrenergic receptors were identified by their similar affinities for epinephrine; these subtypes can, however, be differentiated by selective drugs and by their second messenger generation in response to epinephrine. These receptors are now known to be the products of separate but homologous genes. VPAC1 and VPAC2 are products of distinct genes (Adamou et al., 1995) . The VPAC1 receptor has been cloned from HT-29 colon carcinoma cells and shown to be a 42-kDa protein (Sreedharan et al., 1991) . VPAC2 was cloned from a human placental library (Adamou et al., 1995) . Cross-linking studies in our laboratory have demonstrated a 47-kDa receptor protein in both HT-29 and Molt-4b cells (Wood and O'Dorisio, 1985) . The results of the present study suggest that VPAC1 on HT-29 colonic epithelial cells and VPAC2 on Molt-4b lymphoblasts can be functionally differentiated by their response to VIP 4 -28 .
This may be of functional significance in the intestine wherein VIP modulates water and electrolyte secretion via stimulation of adenylate cyclase in intestinal epithelial cells (Amiranoff et al., 1978) . VIP also seems to modulate secretion of IgA, the major antibody in intestinal secretions (Stanisz et al., 1986) . In the immune system, VIP synthesized and released from eosinophils modulates cytokine production Inhibitor concentrations were bacitracin (1 mg/ml), PMSF (0.5 mM), DFP (5 mM), PA (5 M), ␤-thiorphan (␤-T) (4 g/ml), bestatin (1 mM) and pepstatin (1 mM). Molt-4b lymphoblasts (1 ϫ 10 6 cells/point) were incubated for 5 min at 37°C in the presence of indicated protease inhibitor and adenylate cyclase agonist. Reaction was stopped by the addition of TCA, and cAMP was quantified by radioimmunoassay as described under Materials and Methods. jpet.aspetjournals.org (Weinstock, 1991) . VIP down-regulates IL-2, IL-4 (Iwamoto et al., 1992) , IL-10 (Martinez et al., 1998) , and tumor necrosis factor-␣ (Dewit et al., 1998; Jabrane-Ferrat et al., 1999) and up-regulates antigen-induced interferon-␥ (Jabrane-Ferrat et al., 1999) as well as IL-5 (Mathew et al., 1992) . We have shown that VPAC1 is down-regulated and VPAC2 is upregulated during activation of CD4ϩ T cells (Lara-Marquez et al., 2001 ). VIP and/or similar peptides regulate circadian rhythms; mice lacking the VPAC2 gene fail to adapt to changes in light cycles (Harmar et al., 2002) . The observations reported here suggest that VIP released from nerve endings or eosinophils in the gut can differentially activate enterocytes and lymphocytes. In lymphocytes, VIP seems to be hydrolyzed to VIP 4 -28 by an unknown mechanism ). We now demonstrate that the peptide fragment, VIP 4 -28 , stimulates adenylate cyclase in enterocytes via VPAC1 and inhibits VPAC2-mediated stimulation of adenylate cyclase. Thus, the presence of an antagonist for VPAC2 may have functional significance in the intestine wherein VIP modulates water and electrolytes (Barbezat and Grossman, 1971) in enterocytes expressing VPAC1 (Amiranoff et al., 1978) and also comes in contact with intraepithelial lymphocytes expressing VPAC2.
VPAC1 and VPAC2 are the only known receptors to which VIP binds with high affinity. Although VIP binds to the pituitary adenylate cyclase activating peptide receptor PAC1, VIP has both lower affinity and lower potency as a PAC1 ligand than does pituitary adenylate cyclase activating peptide (Sano et al., 2002) . For this reason, and also because we have no access to a PAC1-expressing human cell line lacking VPAC1 and VPAC2 expression, these studies have not examined the agonist and antagonist activity of VIP, VIP -6 -28 , VIP 4 -28 , and VIP 10 -28 at the PAC1 binding site. If VIP 4 -28 proves to be a potent VPAC1 agonist/VPAC2 antagonist in vivo, its agonist/antagonist activity at the PAC1 binding site would be warranted.
In summary, VIP 4 -28 , a proteolytic product of the major secreted peptide VIP 1-28, is a potent agonist for VPAC1 and a potent antagonist for VPAC2. This identification of an endogenous VPAC2 antagonist has important implications for selective regulation of intestinal secretion and mucosal immune function.
